Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan
CONCLUSIONS: PIK3CA, FGFR1, and BRCA1/2 were the most prevalent actionable alterations among Taiwanese luminal B1 breast cancer. Moreover, PTEN and BRCA1/2 was significantly associated with disease relapse.PMID:38070067 | DOI:10.1007/s12282-023-01524-8 (Source: Breast Cancer)
Source: Breast Cancer - December 9, 2023 Category: Cancer & Oncology Authors: Bo-Fang Chen Yi-Fang Tsai Pei-Ju Lien Yen-Shu Lin Chin-Jung Feng Yen-Jen Chen Han-Fang Cheng Chun-Yu Liu Ta-Chung Chao Jiun-I Lai Ling-Ming Tseng Chi-Cheng Huang Source Type: research
Are breast cancer subtypes different in breast cancer patients with and without hepatitis C virus infection?
Breast Cancer. 2023 Dec 9. doi: 10.1007/s12282-023-01536-4. Online ahead of print.NO ABSTRACTPMID:38070068 | DOI:10.1007/s12282-023-01536-4 (Source: Breast Cancer)
Source: Breast Cancer - December 9, 2023 Category: Cancer & Oncology Authors: Kadri Altundag Source Type: research
Association of molecular subtypes and treatment with survival in invasive micropapillary breast cancer: an analysis of the Surveillance, Epidemiology, and End Results database
CONCLUSION: The prognosis of IMPC was significantly influenced by different molecular subtypes. Chemotherapy and radiotherapy are beneficial in HR+/HER2+ and HR+/HER2- patients. However, they should be used with caution in HR-/HER2- (TN) patients.PMID:38043116 | DOI:10.1007/s12282-023-01523-9 (Source: Breast Cancer)
Source: Breast Cancer - December 3, 2023 Category: Cancer & Oncology Authors: Zhenning Tang Ling Li Xiaoying Huang Yinbing Zhao Lingyan Huang Source Type: research
Annual report of the Japanese Breast Cancer Registry for 2019
Breast Cancer. 2023 Dec 4. doi: 10.1007/s12282-023-01526-6. Online ahead of print.ABSTRACTThis is an annual report by the Japanese Breast Cancer Society regarding the clinical data on breast cancer extracted from the National Clinical Database-Breast Cancer Registry (NCD-BCR) of Japan. Here, we present an updated summary of 98,300 breast cancer cases registered in 2019. The median age at cancer diagnosis was 61 years (interquartile range 49-72 years), and 30.6% of the breast cancer patients were premenopausal. Of the 93,840 patients without distant metastases, 14,118 (15.0%) and 42,047 (44.8%) were diagnosed with stage 0 a...
Source: Breast Cancer - December 3, 2023 Category: Cancer & Oncology Authors: Minoru Miyashita Hiraku Kumamaru Naoki Niikura Yasuaki Sagara Takaaki Konishi Takayuki Iwamoto Naoko Sanuki Kenta Tanakura Masayuki Nagahashi Naoki Hayashi Masayuki Yoshida Chie Watanabe Naoko Kinukawa Masakazu Toi Shigehira Saji Source Type: research
Association of molecular subtypes and treatment with survival in invasive micropapillary breast cancer: an analysis of the Surveillance, Epidemiology, and End Results database
CONCLUSION: The prognosis of IMPC was significantly influenced by different molecular subtypes. Chemotherapy and radiotherapy are beneficial in HR+/HER2+ and HR+/HER2- patients. However, they should be used with caution in HR-/HER2- (TN) patients.PMID:38043116 | DOI:10.1007/s12282-023-01523-9 (Source: Breast Cancer)
Source: Breast Cancer - December 3, 2023 Category: Cancer & Oncology Authors: Zhenning Tang Ling Li Xiaoying Huang Yinbing Zhao Lingyan Huang Source Type: research
Annual report of the Japanese Breast Cancer Registry for 2019
Breast Cancer. 2023 Dec 4. doi: 10.1007/s12282-023-01526-6. Online ahead of print.ABSTRACTThis is an annual report by the Japanese Breast Cancer Society regarding the clinical data on breast cancer extracted from the National Clinical Database-Breast Cancer Registry (NCD-BCR) of Japan. Here, we present an updated summary of 98,300 breast cancer cases registered in 2019. The median age at cancer diagnosis was 61 years (interquartile range 49-72 years), and 30.6% of the breast cancer patients were premenopausal. Of the 93,840 patients without distant metastases, 14,118 (15.0%) and 42,047 (44.8%) were diagnosed with stage 0 a...
Source: Breast Cancer - December 3, 2023 Category: Cancer & Oncology Authors: Minoru Miyashita Hiraku Kumamaru Naoki Niikura Yasuaki Sagara Takaaki Konishi Takayuki Iwamoto Naoko Sanuki Kenta Tanakura Masayuki Nagahashi Naoki Hayashi Masayuki Yoshida Chie Watanabe Naoko Kinukawa Masakazu Toi Shigehira Saji Source Type: research
Association of molecular subtypes and treatment with survival in invasive micropapillary breast cancer: an analysis of the Surveillance, Epidemiology, and End Results database
CONCLUSION: The prognosis of IMPC was significantly influenced by different molecular subtypes. Chemotherapy and radiotherapy are beneficial in HR+/HER2+ and HR+/HER2- patients. However, they should be used with caution in HR-/HER2- (TN) patients.PMID:38043116 | DOI:10.1007/s12282-023-01523-9 (Source: Breast Cancer)
Source: Breast Cancer - December 3, 2023 Category: Cancer & Oncology Authors: Zhenning Tang Ling Li Xiaoying Huang Yinbing Zhao Lingyan Huang Source Type: research
Annual report of the Japanese Breast Cancer Registry for 2019
Breast Cancer. 2023 Dec 4. doi: 10.1007/s12282-023-01526-6. Online ahead of print.ABSTRACTThis is an annual report by the Japanese Breast Cancer Society regarding the clinical data on breast cancer extracted from the National Clinical Database-Breast Cancer Registry (NCD-BCR) of Japan. Here, we present an updated summary of 98,300 breast cancer cases registered in 2019. The median age at cancer diagnosis was 61 years (interquartile range 49-72 years), and 30.6% of the breast cancer patients were premenopausal. Of the 93,840 patients without distant metastases, 14,118 (15.0%) and 42,047 (44.8%) were diagnosed with stage 0 a...
Source: Breast Cancer - December 3, 2023 Category: Cancer & Oncology Authors: Minoru Miyashita Hiraku Kumamaru Naoki Niikura Yasuaki Sagara Takaaki Konishi Takayuki Iwamoto Naoko Sanuki Kenta Tanakura Masayuki Nagahashi Naoki Hayashi Masayuki Yoshida Chie Watanabe Naoko Kinukawa Masakazu Toi Shigehira Saji Source Type: research
Association of molecular subtypes and treatment with survival in invasive micropapillary breast cancer: an analysis of the Surveillance, Epidemiology, and End Results database
CONCLUSION: The prognosis of IMPC was significantly influenced by different molecular subtypes. Chemotherapy and radiotherapy are beneficial in HR+/HER2+ and HR+/HER2- patients. However, they should be used with caution in HR-/HER2- (TN) patients.PMID:38043116 | DOI:10.1007/s12282-023-01523-9 (Source: Breast Cancer)
Source: Breast Cancer - December 3, 2023 Category: Cancer & Oncology Authors: Zhenning Tang Ling Li Xiaoying Huang Yinbing Zhao Lingyan Huang Source Type: research
Annual report of the Japanese Breast Cancer Registry for 2019
Breast Cancer. 2023 Dec 4. doi: 10.1007/s12282-023-01526-6. Online ahead of print.ABSTRACTThis is an annual report by the Japanese Breast Cancer Society regarding the clinical data on breast cancer extracted from the National Clinical Database-Breast Cancer Registry (NCD-BCR) of Japan. Here, we present an updated summary of 98,300 breast cancer cases registered in 2019. The median age at cancer diagnosis was 61 years (interquartile range 49-72 years), and 30.6% of the breast cancer patients were premenopausal. Of the 93,840 patients without distant metastases, 14,118 (15.0%) and 42,047 (44.8%) were diagnosed with stage 0 a...
Source: Breast Cancer - December 3, 2023 Category: Cancer & Oncology Authors: Minoru Miyashita Hiraku Kumamaru Naoki Niikura Yasuaki Sagara Takaaki Konishi Takayuki Iwamoto Naoko Sanuki Kenta Tanakura Masayuki Nagahashi Naoki Hayashi Masayuki Yoshida Chie Watanabe Naoko Kinukawa Masakazu Toi Shigehira Saji Source Type: research
Association of molecular subtypes and treatment with survival in invasive micropapillary breast cancer: an analysis of the Surveillance, Epidemiology, and End Results database
CONCLUSION: The prognosis of IMPC was significantly influenced by different molecular subtypes. Chemotherapy and radiotherapy are beneficial in HR+/HER2+ and HR+/HER2- patients. However, they should be used with caution in HR-/HER2- (TN) patients.PMID:38043116 | DOI:10.1007/s12282-023-01523-9 (Source: Breast Cancer)
Source: Breast Cancer - December 3, 2023 Category: Cancer & Oncology Authors: Zhenning Tang Ling Li Xiaoying Huang Yinbing Zhao Lingyan Huang Source Type: research
Annual report of the Japanese Breast Cancer Registry for 2019
Breast Cancer. 2023 Dec 4. doi: 10.1007/s12282-023-01526-6. Online ahead of print.ABSTRACTThis is an annual report by the Japanese Breast Cancer Society regarding the clinical data on breast cancer extracted from the National Clinical Database-Breast Cancer Registry (NCD-BCR) of Japan. Here, we present an updated summary of 98,300 breast cancer cases registered in 2019. The median age at cancer diagnosis was 61 years (interquartile range 49-72 years), and 30.6% of the breast cancer patients were premenopausal. Of the 93,840 patients without distant metastases, 14,118 (15.0%) and 42,047 (44.8%) were diagnosed with stage 0 a...
Source: Breast Cancer - December 3, 2023 Category: Cancer & Oncology Authors: Minoru Miyashita Hiraku Kumamaru Naoki Niikura Yasuaki Sagara Takaaki Konishi Takayuki Iwamoto Naoko Sanuki Kenta Tanakura Masayuki Nagahashi Naoki Hayashi Masayuki Yoshida Chie Watanabe Naoko Kinukawa Masakazu Toi Shigehira Saji Source Type: research
The effects of breast density on the benefits of mammograms with adjunctive ultrasonography in breast screening
CONCLUSION: We found the benefits of adjunctive ultrasonography with mammography to differ depending on breast density. This could be used to tailor the selection of screening modalities to individuals.PMID:38012337 | DOI:10.1007/s12282-023-01525-7 (Source: Breast Cancer)
Source: Breast Cancer - November 27, 2023 Category: Cancer & Oncology Authors: Akira Nakamura Koji Ohnuki Haruka Takahashi Shin Usami Yuki Ishida Setsuko Shibata Akiko Umemura Yuka Takikawa Atsushi Kano Source Type: research
The effects of breast density on the benefits of mammograms with adjunctive ultrasonography in breast screening
CONCLUSION: We found the benefits of adjunctive ultrasonography with mammography to differ depending on breast density. This could be used to tailor the selection of screening modalities to individuals.PMID:38012337 | DOI:10.1007/s12282-023-01525-7 (Source: Breast Cancer)
Source: Breast Cancer - November 27, 2023 Category: Cancer & Oncology Authors: Akira Nakamura Koji Ohnuki Haruka Takahashi Shin Usami Yuki Ishida Setsuko Shibata Akiko Umemura Yuka Takikawa Atsushi Kano Source Type: research
The effects of breast density on the benefits of mammograms with adjunctive ultrasonography in breast screening
CONCLUSION: We found the benefits of adjunctive ultrasonography with mammography to differ depending on breast density. This could be used to tailor the selection of screening modalities to individuals.PMID:38012337 | DOI:10.1007/s12282-023-01525-7 (Source: Breast Cancer)
Source: Breast Cancer - November 27, 2023 Category: Cancer & Oncology Authors: Akira Nakamura Koji Ohnuki Haruka Takahashi Shin Usami Yuki Ishida Setsuko Shibata Akiko Umemura Yuka Takikawa Atsushi Kano Source Type: research
